(MENAFN- GetNews) Every year, thousands of patients die from anaphylactic shock despite carrying life-saving epinephrine. The reason may be simpler than expected: fear of needles. Studies show up to 25% of adults experience needle phobia, yet nearly all emergency medications still require injection. This disconnect between patient psychology and drug delivery technology represents both a healthcare failure and a multi-billion dollar opportunity.

An Emerging Platform Technology

Nasus Pharma (NYSE:NSRX), which recently completed its NYSE American IPO, may be positioning itself at the forefront of solving this problem. The clinical-stage pharmaceutical company has developed NASAX, a proprietary nasal powder platform that could fundamentally change emergency drug delivery. Unlike the liquid-based intranasal products that currently dominate the market, including Narcan for opioid overdoses and the recently approved Neffy for anaphylaxis, powder-based technology may offer distinct advantages.

The global non-invasive drug delivery market, valued at approximately $15 billion in 2025. Within this landscape, advanced nasal powder platforms could represent a significant technological leap. The potential lies not just in eliminating needles, but in potentially improving drug delivery itself.

The Science Behind Superior Absorption

Research published in Respiratory Drug Delivery reveals why powder formulations may outperform liquids. Powder nasal sprays could reach approximately 70% of the nose's high-absorbent areas, including the middle and olfactory zones. Liquid formulations reach only 36% of these same areas. This difference in distribution patterns may translate directly into faster drug absorption and higher maximum concentrations when seconds count.

The nasal cavity's rich vascular network makes it ideal for rapid drug absorption. Powder formulations may leverage this anatomy more effectively than liquids, which tend to accumulate in lower, less absorbent areas of the nasal cavity. For emergency medications where time equals survival, this distinction could prove critical.

Engineering at the Microscopic Level

Under a microscope, most pharmaceutical powders look chaotic: jagged shapes, random sizes, unpredictable clumps that absorb erratically. NASAX technology may have solved this puzzle by creating perfect spheres, each identical to the next. Think of throwing a handful of rocks versus marbles. The marbles roll smoothly, spread evenly, behave predictably.

The platform produces two types of perfect spheres: tiny ones carrying the medicine and larger lactose particles acting as microscopic delivery trucks. This dual-particle system could explain the superior nasal distribution. Creating these particles has proven so difficult that powder nasal sprays remain extremely rare. Nearly every FDA-approved emergency nasal medication uses liquid. The technical barrier has kept most companies from attempting powder formulations.

Multiple Applications, One Platform

NASAX's versatility extends beyond single applications. Nasus (AMEX:NSRX) has demonstrated the platform's adaptability through NS002 for epinephrine targeting anaphylaxis and NS001 for naloxone addressing opioid overdoses. The company has identified additional proof-of-concept programs such as for acute seizures and organophosphate poisoning. Additional applications are being developed. This suggests the platform could serve as infrastructure for various emergency medications, multiplying its potential value.

The company has already achieved key milestones. It successfully transferred the NS001 technology to GMP FDA-approved facilities and manufactured commercial batches required for regulatory submissions. An expanded partnership with Aptar, a leading global manufacturer of drug delivery systems, provides device integration expertise and manufacturing infrastructure from clinical development through commercialization.

Market Validation

The needle-free emergency medicine market is already proving itself. ARS Pharma's Neffy, the first FDA-approved nasal epinephrine spray, achieved 93% US insurance coverage and captured approximately 4-5% market share within months of its 2024 launch. ARS Pharma now commands a market capitalization of approximately $1 billion, validating both regulatory acceptance and market demand.

The clinical urgency of anaphylaxis treatment underscores why absorption speed may matter more than any other factor. According to research published in the New England Journal of Medicine, anaphylaxis can develop within 3 minutes of exposure, with fatal reactions occurring between 3 to 30 minutes. In analyzed cases of fatal anaphylaxis in children, all deaths occurred in patients who did not receive prompt epinephrine treatment. Those who survived received epinephrine within 30 minutes. The NIH emphasizes that allergic reactions can advance to anaphylaxis within minutes, making immediate treatment essential.

This critical therapeutic window is where NS002's powder formulation could offer its greatest advantage over Neffy's liquid approach. The difference between powder reaching 70% of absorption zones versus liquid's 36% may translate directly into faster therapeutic blood levels. When patients have only minutes before respiratory failure or cardiac arrest, those extra seconds of higher drug concentration could mean the difference between life and death. In anaphylaxis, superior absorption patterns become a matter of survival, not convenience.

The Path Forward

For investors evaluating opportunities in the evolving drug delivery landscape, Nasus Pharma (NYSE: NSRX) seems to present several compelling factors. The company offers platform technology with multiple applications rather than a single product. It has established manufacturing pathways that reduce execution risk. Most importantly, it provides clear differentiation from existing liquid-based approaches.

The transformation toward patient-centric, non-invasive delivery appears to be accelerating. Emergency medications represent a particularly compelling segment where powder-based nasal delivery advantages could be most pronounced. Companies positioned with validated technologies at this intersection could potentially capture significant value as the market evolves. Whether NASAX fulfills this potential will depend on clinical validation and market execution, but the convergence of patient needs, technological capability, and market dynamics suggests the timing may be right for this innovation.

Recent News Highlights:

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

Nasus Pharma Announces Closing of Initial Public Offering

Disclaimer & Disclosure: This article is a form of paid promotional content/advertising. The Author, Wall Street Wire, receives cash compensation from Nasus Pharma Ltd for promotional media services provided on an ongoing subscription basis, This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire/disclosures. We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. This article has was not reviewed or approved by the issuer prior to publication and should not be considered an official communication by it.

MENAFN03112025003238003268ID1110289980